Advertisement
Organisation › Details
Novartis (Group)
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. *
Start | 1996-12-20 merged | |
Predecessor | Ciba-Geigy (Group) | |
Industry | CHEMICALS | |
Person | Narasimhan, Vasant (Vas) (Novartis 201408– Global Head Developm Novartis Pharma before Global Head Developm Vaccines | |
Person 2 | Reinhardt, Jörg (Novartis 201308– Board Chairman before Bayer 201008– CEO Bayer HealthCare AG before Novartis COO) | |
Region | Basel BS | |
Country | Switzerland | |
City | 4002 Basel BS | |
Tel | +41-61-324-2200 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | J: more than 100,0 (2019-12-31) |
Currency | USD | |
Annual sales | 47,498,000,000 (sales, net, continued operations, consolidated (2019) 2019-12-31) | |
Profit | 7,147,000,000 (2019-12-31) | |
Cash | 9,485,000,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-24 |
Advertisement
More documents for Novartis (Group)
- [1] PeptiDream Inc.. (4/30/24). "Press Release: PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis". Kanagawa....
- [2] Scinai Immunotherapeutics Ltd.. (2/13/24). "Press Release: Scinai Welcomes Liat Halpert as Head of Business Development and Sales". Jerusalem....
- [3] Shanghai Argo Biopharmaceutical Co., Ltd.. (1/7/24). "Press Release: Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis". Shanghai....
- [4] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
- [5] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
- [6] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
- [7] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [8] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
- [9] BioGeneration Ventures B.V.. (7/19/23). "Press Release: Dr. Markus Kalousek and Dr. Andrew Lightfoot Join BGV as Venture Partners". Amsterdam....
- [10] Mediar Therapeutics Inc.. (3/15/23). "Press Release: Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top